|   Press Release

Atlas Venture Announces $250 Million Opportunity Fund

Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, today announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed fundraise. With Atlas Venture Opportunity Fund I (AVOF I), the firm will invest in existing Atlas portfolio companies as they progress.

Read more.


  |   From the Trenches

The World Cup of Conferences

Nine presentations, three press releases, forty-two satellite meetings. One conference.

This blog was written by Jason Gardner, CEO of Magenta Therapeutics and Liverpool soccer fan, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Generations: Talent Dispersion in Biotechnology

The evening of April 26, 2009, I walked from my hotel room to the nearest bar. The bar was called the Asgard, and it was on an unfamiliar road called Sidney Street, in a place I barely knew called Cambridge, Massachusetts. I wanted some comfort food before my big job interview at Millennium Pharmaceuticals the next day. I ordered a beer and burger, but as I took my first sip, a little voice in the back of my head reminded me that expensing a beer was probably not the best idea when traveling for an interview. I paid for the drink myself and stuffed the receipt into my jeans pocket.

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Partnered with Novartis, tiny Cadent jumps out of stealth with $40M round for its CNS pipeline

A small Cambridge, Massachusetts-based company is hoping its bet on CNS drugs using a well established pharmaceutical approach — allosteric modulators — will cement its place as a biotech powerhouse in the years to come. Cadent Therapeutics — currently a 9-person team — has already found a partner in Novartis $NVS.

Read more.


  |   From the Trenches

Fleece vs Future: How Small Companies Can Help Build Biotech Talent

A lot has been written about the biotech talent war in the Boston area including the availability of talent as the major limitation to venture creation and the increasingly lavish perks designed to attract and retain experienced staff. As the leader of an organization attempting to grow within this ecosystem, I am acutely aware of the challenges.

This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches features of LifeSciVC.

Read more.